Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Research & Development (2016 - 2025)

Historic Research & Development for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to $22.5 million.

  • Integra Lifesciences Holdings' Research & Development fell 1814.84% to $22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $105.4 million, marking a year-over-year decrease of 282.16%. This contributed to the annual value of $115.4 million for FY2024, which is 1073.5% up from last year.
  • As of Q3 2025, Integra Lifesciences Holdings' Research & Development stood at $22.5 million, which was down 1814.84% from $27.0 million recorded in Q2 2025.
  • In the past 5 years, Integra Lifesciences Holdings' Research & Development ranged from a high of $31.2 million in Q4 2024 and a low of $20.1 million during Q2 2021
  • For the 5-year period, Integra Lifesciences Holdings' Research & Development averaged around $25.7 million, with its median value being $25.8 million (2021).
  • Its Research & Development has fluctuated over the past 5 years, first surged by 3480.5% in 2021, then crashed by 1814.84% in 2025.
  • Integra Lifesciences Holdings' Research & Development (Quarter) stood at $24.7 million in 2021, then rose by 8.32% to $26.8 million in 2022, then decreased by 9.33% to $24.3 million in 2023, then rose by 28.52% to $31.2 million in 2024, then decreased by 28.05% to $22.5 million in 2025.
  • Its Research & Development was $22.5 million in Q3 2025, compared to $27.0 million in Q2 2025 and $24.7 million in Q1 2025.